# Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

> **NCT00025675** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 105 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00025675
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10-09
- **Primary completion:** 2006-07-05
- **Final completion:** 2010-01-02
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025675, "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00025675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*